A special committee of independent directors at consumer genetic testing company 23andMe turned down CEO Anne Wojcicki's plan on Monday to buy all the company's shares and take it private.
Why it matters: Wojcicki's take-private plan was the latest salvo in a more than year-long effort to preserve struggling 23andMe, hit hard by the demise of home DNA testing.
